首页> 外文期刊>Brazilian Journal of Medical and Biological Research >Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A
【24h】

Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A

机译:槲皮素脂质体对刀豆球蛋白A诱导的急性肝炎和肝纤维化的抑制作用

获取原文
获取外文期刊封面目录资料

摘要

Immune response plays an important role in the development of hepatic fibrosis. In the present study, we investigated the effects of quercetin on hepatitis and hepatic fibrosis induced by immunological mechanism. In the acute hepatitis model, quercetin (2.5 mg/kg) was injected iv into mice 30 min after concanavalin A (Con A) challenge. Mice were sacrificed 4 or 24 h after Con A injection, and aminotransferase tests and histopathological sections were performed. Treatment with quercetin significantly decreased the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Consistent with this observation, treatment with quercetin markedly attenuated the pathologic changes in the liver. A hepatic fibrosis model was also generated in mice by Con A challenge once a week for 6 consecutive weeks. Mice in the experimental group were treated with daily iv injections of quercetin (0.5 mg/kg). Histopathological analyses revealed that treatment with quercetin markedly decreased collagen deposition, pseudolobuli development, and hepatic stellate cells activation. We also examined the effects of quercetin on the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and transforming growth factor beta (TGF-β) pathways by immunohistochemistry and real-time reverse transcriptase-polymerase chain reaction (RT-PCR). NF-κB and TGF-β production was decreased after treatment with quercetin, indicating that the antifibrotic effect of quercetin is associated with its ability to modulate NF-κB and TGF-β production. These results suggest that quercetin may be an effective therapeutic strategy in the treatment of patients with liver damage and fibrosis.
机译:免疫反应在肝纤维化发展中起重要作用。在本研究中,我们研究了槲皮素对免疫机制诱导的肝炎和肝纤维化的影响。在急性肝炎模型中,在刀豆球蛋白A(Con A)攻击后30分钟,将槲皮素(2.5 mg / kg)静脉内注射到小鼠中。 Con A注射后4或24 h处死小鼠,并进行氨基转移酶测试和组织病理学切片。槲皮素治疗可显着降低丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)的水平。与该观察结果一致,槲皮素治疗显着减轻了肝脏的病理变化。每周一次连续6周通过Con A攻击在小鼠体内产生肝纤维化模型。实验组的小鼠每天静脉注射槲皮素(0.5 mg / kg)。组织病理学分析显示,用槲皮素治疗可显着减少胶原蛋白沉积,假小叶发育和肝星状细胞活化。我们还通过免疫组织化学和实时逆转录酶-聚合酶链反应研究了槲皮素对活化B细胞核因子kappa-轻链增强子(NF-κB)和转化生长因子β(TGF-β)途径的影响(RT-PCR)。槲皮素治疗后NF-κB和TGF-β的产生减少,表明槲皮素的抗纤维化作用与其调节NF-κB和TGF-β产生的能力有关。这些结果表明槲皮素可能是治疗肝损害和纤维化患者的有效治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号